Cancer diagnostics Exosome Diagnostics specializes in minimally invasive molecular diagnostics using exosome-based liquid biopsies to detect cancer-associated genes and mutations, presenting a clear sales angle for oncology tests and companion diagnostics partnerships.

Expanded test kits Recent and past launches include at-home collection kits and urine/blood based testing, creating opportunities to upsell additional liquid biopsy panels or bundled solutions for urology, prostate cancer, and general oncology screening.

Strategic partnerships History of collaborations with biopharma and diagnostics players (e.g., Intezyne, Bio-Techne) suggests a favorable environment for co-development, validation studies, and large-scale clinical trials as a route to broaden adoption.

Growth signals Company has mid-size employment and sizable revenue with ongoing investments and partnerships, indicating potential capacity for scaled commercial rollouts, field support, and reimbursement navigation services in key markets.

Regulatory readiness ISO 13485 and related quality systems indicate strong regulatory and quality control foundations, enabling faster path to market for new exosome-based assays and potential audits or certification services as a value add.